Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma.
Wang J, Ferrena A, Zhang R, Singh S, Viscarret V, Al-Harden W, Aldahamsheh O, Borjihan H, Singla A, Yaguare S, Tingling J, Zi X, Lo Y, Gorlick R, Schwartz EL, Zhao H, Yang R, Geller DS, Zheng D, Hoang BH.
Wang J, et al. Among authors: zhang r.
Oncogene. 2024 Mar;43(13):962-975. doi: 10.1038/s41388-024-02942-4. Epub 2024 Feb 14.
Oncogene. 2024.
PMID: 38355807
Free PMC article.